Trial Profile
Visualizing VEGF Producing Lesions in Von Hippel-Lindau Disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Haemangioblastoma; Neuroendocrine tumours; Pancreatic cancer; Phaeochromocytoma; Renal cell carcinoma; Von Hippel-Lindau disease
- Focus Diagnostic use
- Acronyms VHLimage
- 18 May 2017 New trial record